In June 2008, Cognitive Pharmaceuticals Ltd merged with Mithridion, Inc - also an SBIR involved firm founded in 2004 - continuing under the Mithridion name. With both focused on developing therapies for Alzheimer's disease and central nervous disorders, merger of the two firms enabled a drug candidate to enter clinical trials. Mithridion maintained its headquarters and preclinical drug research laboratories in Madison, and engaged in early drug discovery and clinical drug development operations in Toledo, where the lead compound was developed. Designed to slow down the disease process, the merged company's first Alzheimer's drug candidate, MCD-386, was developed with technology licensed from the University of Toledo's College of Pharmacy. In 2013, the firm ceased operations.
